ImmunityBio (IBRX) Other financing activities (2018 - 2021)

ImmunityBio (IBRX) has 4 years of Other financing activities data on file, last reported at -$2.6 million in Q4 2021.

• Other financing activities for Q4 2021 came in at -$2.6 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2022 was -$1.2 million (down 182.86% YoY), and the FY2021 annual result was $1.4 million, changed N/A from the prior year.
• Other financing activities slipped to -$2.6 million in Q4 2021 per IBRX's latest filing, from $1.4 million in the prior quarter.
• Over five years, Other financing activities peaked at $2.6 million in Q1 2021 and troughed at -$2.6 million in Q4 2021.
• A 4-year average of $162111.1 and a median of $40000.0 in 2019 frame the typical range for Other financing activities.
• The sharpest annual moves came in 2020 and 2021: Other financing activities sank 507.5% in 2020, then surged 2033.33% in 2021.
• A 4-year view of Other financing activities shows it stood at $50000.0 in 2018, then sank by 232.0% to -$66000.0 in 2019, then sank by 146.97% to -$163000.0 in 2020, then slumped by 1488.34% to -$2.6 million in 2021.
• Business Quant data shows IBRX's Other financing activities at -$2.6 million in Q4 2021, $1.4 million in Q3 2021, and $2.6 million in Q1 2021.